PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

被引：0

作者：

Paz-Ares, L. ^{[1
]}

Goldman, J. W. ^{[2
]}

Garassino, M. C. ^{[3
]}

Dvorkin, M. ^{[4
]}

Trukhin, D. ^{[5
]}

Statsenko, G. ^{[6
]}

Hotta, K. ^{[7
]}

Ji, J. H. ^{[8
]}

Hochmair, M. J. ^{[9
]}

Voitko, O. ^{[10
]}

Havel, L. ^{[11
]}

Poltoratskiy, A. ^{[12
]}

Losonczy, G. ^{[13
]}

Reinmuth, N. ^{[14
]}

Shrestha, Y. ^{[15
]}

Patel, N. ^{[16
]}

Mann, H. ^{[17
]}

Jiang, H. ^{[18
]}

Ozguroglu, M. ^{[19
]}

Chen, Y. ^{[20
]}

机构：

[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Med, Los Angeles, CA 90095 USA

[3] Ist Nazl Tumori, Fdn IRCCS, Thorac Unit, Milan, Italy

[4] BHI Omsk Reg Clin Oncol Dispensary, Dept Oncol, Omsk, Russia

[5] Natl Med Univ, Oncol Dept, Odessa, Ukraine

[6] Omsk Reg Canc Ctr, Dept Med Oncol, Omsk, Russia

[7] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[8] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Internal Med, Chang Won, South Korea

[9] Krankenhaus Nord, Dept Resp & Crit Care Med, Karl Landsteiner Inst Lung Res & Pulm Oncol, Krankenhaus Nord, Vienna, Austria

[10] Kyiv City Clin Oncol Ctr, Dept Chemotherapy, Kiev, Ukraine

[11] Charles Univ Prague, Thomayer Hosp, Fac Med 1, Prague, Czech Republic

[12] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia

[13] Semmelweis Univ, Fac Med, Budapest, Hungary

[14] Asklepios Lung Clin, Thorac Oncol, Munich, Germany

[15] AstraZeneca, Translat Med, Gaithersburg, MD USA

[16] AstraZeneca, Patient Reported Outcomes, Gaithersburg, MD USA

[17] AstraZeneca, Res & Dev, Cambridge, MD USA

[18] AstraZeneca, Global Med Dev, Gaithersburg, MD USA

[19] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Internal Med, Istanbul, Turkey

[20] Canc & Hematol Ctr Western Michigan, Med Oncol, Grand Rapids, MI USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA89

引用

页码：928 / +

页数：2

共 50 条

[21] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES-SCLC): exploratory analysis of patients with long-term clinical benefit in CASPIAN
Reinmuth, N.
Paz-Ares, L. G.
Panse, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152
[22] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Hochmair, M. J.
Ji, J. H.
Ozguroglu, M.
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 : S97 - S98
[23] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
Goldman, Jonathan W.
Garassino, Marina Chiara
Chen, Yuanbin
Hotta, Katsuyuki
Poltoratskiy, Artem
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Statsenko, Galina
Voitko, Oleksandr
Conev, Nikolay V.
Bondarenko, Igor
Mann, Helen
Xie, Mingchao
Shrestha, Yashaswi
Chugh, Priti
Dalvi, Tapashi
Paz-Ares, Luis
Bischoff, Helge
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 161 - 161
[24] Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
Nishio, M.
Ji, J. H.
Hotta, K.
Chiu, C-H.
Lee, J-S.
Azuma, K.
Kim, S-W.
Wu, S-Y.
Dvorkin, M.
Trukhin, D.
Havel, L.
Hochmair, M. J.
Ozguroglu, M.
Bar, J.
Chen, Y.
Goldman, J. W.
Byrne, N.
Laud, P. J.
Shire, N.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2019, 30
[25] Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.
Ozgurogiu, Mustafa
Goldman, Jonathan W.
Chen, Yuanbin
Garassino, Marina Chiara
Medic, Nenad
Mann, Helen
Chugh, Priti
Dalvi, Tapashi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
Chen, Yuanbin
Paz-Ares, Luis
Reinmuth, Niels
Garassino, Marina Chiara
Statsenko, Galina
Hochmair, Maximilian J.
Oezgueroglu, Mustafa
Verderame, Francesco
Havel, Libor
Losonczy, Gyoergy
Conev, Nikolay, V
Hotta, Katsuyuki
Ji, Jun Ho
Spencer, Stuart
Dalvi, Tapashi
Jiang, Haiyi
Goldman, Jonathan W.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
[27] IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
Califano, R.
Kazarnowicz, A.
Karaseva, N.
Sanchez, A.
Liu, S. V.
Horn, L.
Quach, C.
Yu, W.
Kabbinavar, F.
Lam, S.
Mansfield, A.
ANNALS OF ONCOLOGY, 2018, 29 : 17 - 17
[28] Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
Goldman, Jonathan W.
Garassino, Marina Chiara
Chen, Yuanbin
Ozguroglu, Mustafa
Dvorkin, Mikhail
Trukhin, Dmytro
Statsenko, Galina
Hotta, Katsuyuki
Ji, Jun Ho
Hochmair, Maximilian J.
Voitko, Oleksandr
Havel, Libor
Poltoratskiy, Artem
Losonczy, Gyorgy
Reinmuth, Niels
Patel, Nikunj
Laud, Peter J.
Shire, Norah
Jiang, Haiyi
Paz-Ares, Luis
LUNG CANCER, 2020, 149 : 46 - 52
[29] Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Cheng, Y.
Wang, J.
Yao, W.
Yu, Y.
Zang, A.
Cao, L.
Lv, D.
Li, S.
Meng, Z.
Zhang, J.
Guo, Q.
Huang, D.
Liu, A.
Liu, J.
Mao, W.
Tang, K.
Zhang, Y.
Chen, E.
Wang, Z.
Zheng, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1673 - S1673
[30] Durvalumab (D) ± Tremelimumab (T) plus Platinum Etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of Patients with Long-term Survival in the CASPIAN Study
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Hochmair, M. J.
Ozguroglu, M.
Ji, J. H.
Statsenko, G.
Voitko, O.
Conev, N., V
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.
Alt, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 101 - 102

← 1 2 3 4 5 →